A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

This study is testing a new drug called JMKX001899 combined with other therapies for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene mutation called KRAS G12C. This mutation is found in a subset of lung cancers and is a target for newer precision medicines. **You may be eligible if...** - You have advanced NSCLC (stage IIIB, IIIC, or IV) that cannot be removed by surgery - Your tumor has been tested and found to have a KRAS G12C mutation - Your tumor does not have other driver gene mutations that have approved targeted treatments - You have measurable disease on scans - You are in good physical condition (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has spread to the brain lining (carcinomatous meningitis) or is causing spinal cord compression - You have another active cancer - Your organs are not functioning well enough for the treatment - You have recently received certain other cancer therapies Talk to your doctor to see if this trial is right for you.